OncoMatch/Clinical Trials/NCT07188090
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Is NCT07188090 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Plerixafor and Gcsf for multiple myeloma.
Treatment: Plerixafor · Gcsf — This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome. The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: stem cell mobilization (G-CSF, plerixafor, G-CSF biosimilars) — mobilization
Patients must have undergone stem cell mobilization with the combination of G-CSF or biosimilars with plerixafor or G-CSF or biosimilars alone
Lab requirements
Kidney function
serum creatinine ≤ 2.0 mg/dl and/or creatinine clearance of > 40 ml/min (excludes multiple myeloma patients receiving high dose melphalan conditioning)
Liver function
serum bilirubin <1.8, ast or alt < 2.5x upper limit of normal
Cardiac function
lvef of ≥40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Thomas Jefferson University Hospital · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify